Of the remaining three enzymes on our list, we focused on PCK1 (phosphoenolpyruvate carboxykinase 1) given the availability of a pharmacological inhibitor and its heightened expression in normal liver (Uhlén et al., 2015), suggesting potential mimicry of hepatocytes by CRC cells during adaptation to the liver microenvironment. This evidence concerns the gene PCK1 and colorectal carcinoma.